Chargement en cours...
Standard ATG Dosing Results in Poorer Outcomes in Overexposed Patients after Ex vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation
Anti-thymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric we...
Enregistré dans:
| Publié dans: | Biol Blood Marrow Transplant |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7302932/ https://ncbi.nlm.nih.gov/pubmed/30831208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.02.021 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|